New findings add to evidence that people with a certain version of a gene are less likely to develop severe COVID-19.
Earlier research had identified a specific group of genes, called the OAS1/2/3 gene cluster, as being involved in the risk for severe COVID-19. One version of a gene in that cluster – passed down from Neanderthals – appeared to protect against severe disease, reducing the risk by about 23%. The earlier research was done mainly in people of European ancestry.
According to a report published in Nature Genetics, researchers now see the same association of this genetic variant with less severe COVID-19 in people of African ancestry.
“The fact that individuals of African descent had the same protection allowed us to identify the unique variant in the DNA that actually protects from COVID-19 infection,” coauthor Dr. Jennifer Huffman of said in a statement.
OAS genes are involved in a cascade of effects that help cells fight viruses, the researchers said. Understanding of these genes and their effect on COVID-19 risks could aid development of future drugs, they added.
Fewer Delta breakthroughs with Moderna vs Pfizer/BioNTech
When the Delta variant of the coronavirus was prevalent in the United States, recipients of two doses of Moderna’s (MRNA.O) mRNA vaccine were less likely to experience a breakthrough infection – and if they did, were slightly less likely to be hospitalized – than recipients of two doses of the mRNA vaccine from Pfizer and BioNTech , a large study found.
Researchers analyzed health records of more than 637,000 vaccine recipients who were not previously infected with the virus and had not gotten a booster shot. As reported on Thursday in JAMA, breakthrough infections steadily increased every month from July to November 2021, with higher rates in the Pfizer/BioNTech group.
In November, there were 2.8 cases among every thousand people vaccinated with the Pfizer/BioNTech shots, compared to 1.6 cases per thousand recipients of the Moderna vaccines.
The vaccines protected equally well against death, but the hospitalization rate was 12.7% for infected Moderna recipients and 13.3% for Pfizer/BioNTech recipients. When the researchers compared 62,584 Moderna recipients to a closely-matched equal-sized group of Pfizer/BioNTech recipients, the risk for breakthrough infection was 15% lower in the Moderna group.
“Although there is a difference in breakthrough infections, both vaccines are highly protective against SARS-COV2 infection and especially against the most severe consequences of infection,” said coauthor Pamela Davis of Case Western Reserve University School of Medicine in a statement.
